Mineralocorticoid receptors (MRs) are implicated in the pathology of hypertension. MR
blockers are recommended for the treatment of salt-sensitive or resistant hypertension …

Mineralocorticoid receptor (MR) blockers are very beneficial for patients with hypertension
and primary aldosteronism (PA). We investigated the efficacy and safety of a newly available …

This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, open-label
comparator study to investigate the efficacy and safety of esaxerenone (CS-3150), a novel …

The steroidal mineralocorticoid receptor (MR) antagonists, spironolactone and eplerenone,
decrease blood pressure, and attenuate the progression of chronic kidney disease (CKD) …

This study investigated the long-term antihypertensive effects of esaxerenone, a novel
nonsteroidal mineralocorticoid receptor blocker, alone or in combination with a calcium …

Esaxerenone (MINNEBRO™)—a novel oral, non-steroidal, selective mineralocorticoid
receptor blocker—is being developed by Daiichi Sankyo for the treatment of hypertension …

Renin–angiotensin system inhibitors are recommended for treating hypertension with
chronic kidney disease. The addition of a mineralocorticoid receptor blocker may be one …

Nonsteroidal mineralocorticoid receptor antagonists (MRAs) are a new class of drugs
developed to address the medical need for effective and safer treatment to protect the kidney …

In two clinical trials on the antihypertensive effects of the mineralocorticoid receptor
antagonist eplerenone 397 essential hypertensives were dose titrated (50, 100, and 200 …

Mineralocorticoid receptor antagonists (MRAs) are commonly used to reduce blood
pressure, left-ventricular hypertrophy, and urinary albumin excretion in patients with …